Life Sciences Archive » May, 2018

Life Sciences - May, 2018

319 articles

• Ex-Katten Atty's Inflation Claim Lacks Evidence, Feds Say
• ITC To Investigate Chinese Cholesterol Test Strips
• Anthem, Express Scripts Fight Pricing Suit In 2nd Circ.
• 6th Circ. Affirms Freeze On Disbarred Fen-Phen Atty's Assets
• 'Copycats' Can't Push Zetia Antitrust MDL To NY, Panel Told
• 1 Firm Leaps Ahead In May As IPO Market Gathers Steam
• FDA Targets Anti-Generic Foot-Dragging By Big Drugmakers
• SEC Sues Hemp Health Products Co. Over Illicit Stock Sales
• Feds To Depose 12 New Docs In FCA Case Over Hep B Tests
• NY Doc Gets 4 Years For Part In $100M Referral Bribe Scheme
• 'Opioid Babies' Need Separate Track In MDL, Attys Say
• BigLaw Blogs In A Post-GDPR Marketing Universe
• Pa. Pharmacy Owners Ink $3.2M False Billing Settlement
• Boston Scientific Enters $608M Transfer Pricing Deal With IRS
• HHS Medicare Drug Reimbursement Cap Illegal, Suit Says
• Opioid MDL Order Shows Need For Broad Funding Disclosure
• Investors Clinch $18M Deal With Aveo, With 30% For Attys
• Ixchel Asks 9th Circ. To Revive Biogen Antitrust Claims
• Jury Must Hear Wife's Role At Insider Trades Trial, Feds Say
• Groups Urge 9th Circ. To Keep ACA Birth Control Rules Halted
• $395K Atty Fees In Clovis Director Pay Deal Get Chancery OK
• Investors Spar For Lead In Mass. Bioscience Class Action
• FDA Issues Challenge For New Tech To Fight Opioid Crisis
• Insys Sales Rep Pleads Guilty To Opioid Kickback Scheme
• FTC, NY Can't Revive Memory-Booster Suit, 2nd Circ. Told
• GSK, Reed Smith Atty's Widow Spar Over Case's Fiscal Impact
• Blood Test Co. Says Rival Falsely Advertised FDA Status
• Deals Rumor Mill: Allergan, Ant Financial, Oman Oil
• FDA's Youth E-Cig Blitz Could Go Much Further
• The Potentially Far-Reaching Impact Of Sports Betting Case
• J&J Faces Start Of Latest Asbestos-In-Talc Trial In Calif.
• Calif. Appeals Court Shuts Down Biotech Shareholder Suit
• Fla. Gov. Asked To Drop Smokable Med. Marijuana Appeal
• Suits Show Conflict Even At BigLaw's Best Places For Women
• Reform Or Retreat? UK Firms Eye Next Steps On Pay Data
• How Women Are Changing The Law Firms They Lead
• The Best Law Firms For Female Partners
• Duane Morris Adds 7 IP Attys From Vedder Price
• Opioid Suit Against McKesson Doesn't Fit In MDL, Tribe Says
• Bayer, Monsanto Win US Clearance For $62B Deal
• Besins Cut Loose From Testosterone Replacement MDL
• Biotech Startup, Music Streamer Launch IPOs Totaling $158M
• Medical Supplier Pays Feds $1.9M To End FCA Suit
• BakerHostetler Nabs Cairncross Corporate Finance Pro
• High Court Won't Hear Abilify Whistleblowers' FCA Claims
• Shire Stockholders Sue AbbVie Over Failed Merger
• The 2018 Law360 Glass Ceiling Report
• Alibaba Sells Pharmacy Assets To Health Unit For $1.35B
• Analyzing The Economics Of Litigation Funding
• Rule 23 Changes: How Electronic Notice Can Save Money
• Law360's Glass Ceiling Report, By The Numbers
• The Best Law Firms For Female Attorneys
• What Does Gender Parity In The Legal Industry Look Like?
• How We Got Here: A Look Back At Trailblazing Women In Law
• Law360's Pro Say: Why Are All The Partners Still Men?
• Stakes High As GSK Takes Generics Liability Row To 7th Circ.
• Printed Matter Doctrine Case Could Offer New Patent Attack
• Jury Awards $1.2M Over Vein Perforated By Medical Device
• 5 Flash Points As FDA Gets Earful On Compounding Guidance
• Biotechs Lead Wave Of New IPOs Filling June Pipeline
• Weeks Before Oral Args, Mylan Drops AstraZeneca IP Appeal
• Jury Deadlocks In Latest Trial Over J&J Talc And Asbestos
• Buyers Can't Bar Testimony In Teva Pay-For-Delay Suit
• Self-Policing Animal Research: Another Bad Idea From USDA
• A Wish For Nonexistent Cheap Drugs Is Not Standing To Sue
• J&J Claims $70M Award In Surgical Stapler Case Is Unjustified
• Asbestos In J&J Talc Killed 30-Year-Old Atty, Jury Told
• Latham, Goodwin Lead 2 Biotech IPOs Raising $227M
• Procaps Hits Carlton Fields With $15M Malpractice Suit
• Howmedica's Decade Of Misconduct Won Zimmer $13M Fees
• Chinese Co.'s Suit Over GSK Probe Tied To US, 3rd Circ. Told
• Hatch-Waxman Post-TC Heartland: What You Need To Know
• Keys To Protecting Communications With Litigation Funders
• Pfizer Pays $24M To End Medicare Copay Kickback Claims
• Jury Hits J&J With $4M Punitives In Talc Cancer Trial
• J&J Hit With $21.7M Talc Asbestos Cancer Verdict In Calif.
• SG Urges High Court To Take Up Merck's Fosamax Appeal
• NY Doc Convicted For Distributing Opioids That Killed 2
• Dexcom Hit With Atty Fees For 'Bad Faith' Patent Suit
• Fed. Circ. Upholds Most Of Bovine Breeding Patent Verdict
• J&J Talc Supplier Challenges Evidence In $117M Verdicts
• FDA Wants Risky OTC Teething Treatments Pulled Off Market
• 'Queen Of Toxic Torts' Leaves Quinn Emanuel For Dechert
• UCB's Epilepsy Drug Patent Win Upheld By Fed. Circ.
• Biosimilars Imperiled By Big Drug Rebates, FDA Chief Warns
• Impax Dismissal Offers Clues On Pay-For-Delay Under Actavis
• CORRECTED: Convictions Don't Mean Valeant Is Off The Hook
• Teva Urges Justices To Reject Fed. Circ. On-Sale Bar Appeal
• Norton Rose Loses 14 Health, Life Sci Attys To Reed Smith
• Cherokees Slam Drug Cos.' Bid To Pause Opioid Suit
• Trade Rep Hints At More CFIUS Scrutiny Of Biotech Deals
• Lessons From FDA Draft Guidance On Multifunctional Devices
• No Asbestos In J&J Talc Mines, SC Mesothelioma Jury Hears
• Pa. Panel Revives Suit Linking Man's Leukemia To Pesticides
• Ill. Robitussin Buyers Slam Bid To Toss Nationwide Claims
• Ex-Insys Execs Rail Against 'Inflammatory' RICO Indictment
• House Sends 'Right To Try' Treatments Bill To Trump
• Covington Picks Up 2 Kirkland Partners To Lead PE Practice
• Express Scripts Beats Investor Suit Over Anthem Disclosures
• GSK Gets Generic Suits Tossed From Zofran MDL
• 9th Circ. Urged To Keep ACA Birth Control Rules Blocked
• FDA Warning Wire: Rodent Feces At Mass. Candy Plant
• Sanofi Must Divulge Docs In FCA Fight Over Cancer Drug
• CPSC Steps Up Action On Safe Product Packaging Standards
• Ex-Manager, CEO Convicted In $9.7M Valeant Kickback Plot
• Deal In CVS False Ad Suit Shouldn't Get OK, Judge Says
• Sonoma Pharma Can Likely Pursue Trade Secret Claims
• Tribe Says It's Not Just 'Collecting A Check' From Patents
• DLA Piper Picks Up NJ Corporate Atty From Morgan Lewis
• Pillsbury Adds IP Duo In Calif. To Lead Taiwan Practice
• Calif. County Must Face $77M Hemp Seizure Suit, Court Told
• High Court Won't Look At 3rd Circ. Ruling On Eyedrop Size
• Justices Turn Away Solvay FCA Off-Label Marketing Case
• Gilead Again Pushes To Block Truvada Generic
• Introducing The Legal Industry To Millennial Business Owners
• Pa. Appeals Court Urged To OK Philly Mesh Case Jurisdiction
• FTC Admin. Judge Says Endo-Impax Opana Deal Is Lawful
• Fla. Argues To Keep Stay During Pot 'Right To Grow' Appeal
• Tribes Insist On Being Heard In Noisy Opioid MDL
• DEA Drops Enforcement Order Against Opioid Distributor
• Taxation With Representation: Gibson, Freshfields, Wachtell
• NantKwest Investors See Suit Over IPO Tossed Over Standing
• Illumina Can't Enforce Fetal DNA Testing Patent, Natera Says
• 9th Circ. Revives Vitamin E Labeling Row Over Heart Claims
• 7 Firms To Guide IPO Lineup Projected To Surpass $1.2B
• Praxair And The Printed Matter Doctrine
• Advertiser Self-Regulation And Class Actions: Part 3
• Duke Wants Sanctions Over FCA Whistleblower's Convos
• Highlights Of Proposed Medicare Payment And Policy Rules
• A Proposed Approach For High Court In Vitamin C Case
• $9.7M Valeant Payment Was Legal, Ex-Execs Argue In Closing
• FDA Shames Anti-Generic Tactics, Putting Onus On Congress
• Ex-NJ Lab Workers Sentenced In $100M Bribery Scheme
• Exclusivity 'Didn't Require Success,' Amgen Tells DC Circ.
• Osco Drug Sued Over 20 Faxes A Day Promoting Drug Refills
• Mass. Doctor's Kickback Convictions Are Fair, Judge Says
• Deals Rumor Mill: Anglo, Aspen, Thoma Bravo
• Advertiser Self-Regulation And Class Actions: Part 2
• A Chat With Perkins Practice Management Chief Toby Brown
• GSK, Zofran Users To Pick 16 Potential MDL Bellwether Cases
• A Look Inside Trump's 4-Point Plan For Curbing Drug Prices
• Titan Of The Plaintiffs Bar: The Lanier Law Firm's Mark Lanier
• Retailers Led By Walgreens Sue Allergan Over Restasis IP
• Biolitec Counsel Can't Dodge Sanction For Stonewalling
• Fed. Circ. Nixes More Of Inomax Patent After PTAB Review
• Church & Dwight To Face Trimmed Supplement Labeling Row
• Fed. Circ. Upholds Endo's Opioid Patent Win Against Generics
• Feds Show Valeant Jury Spending Records, Doctored Emails
• Deals Rumor Mill: Tianqi, SoftBank, CVC
• Novartis, Par Hit With Pay-For-Delay Suit Over Exforge
• Ill. Jury Finds For AbbVie In AndroGel Bellwether Trial
• Tennis Org Wants $10M Blood Test Injury Suit Arbitrated
• Man Asks Fla. Justices For Right To Grow Pot During Appeal
• DOJ, Microsoft Urge Fed. Circ. To Find Tribes Can Face IPRs
• FCA Questions That High Court May Address Next Term
• 3 Firms Guide PE-Backed Hearing Aid Co.'s €7B Merger
• Advertiser Self-Regulation And Class Actions: Part 1
• No Smoke But Alarms Are Ringing: Insurance For E-Cigarettes
• Why Won't Judicial Nominees Affirm Brown V. Board Of Ed?
• Fed. Circ. Applies Teva Deference In 2 Types Of Cases
• Wachtell Reps Zoetis In $2B Deal For Animal Diagnostics Co.
• Novartis GC Steps Down After News Of Cohen Payments
• The Lawyers' Guide To Cloud Computing
• Tribal Patent Pacts An 'Assault' On IPR System, Fed. Circ. Told
• Defense Buffeted By Tough Rulings In Valeant Kickback Trial
• ZimmerBiomet Scores $13M In Fees In Howmedica IP Fight
• GSK Says W.Va. High Court Opinion Backs 7th Circ. Appeal
• Dartmouth Says PTAB Abused Discretion In Post-SAS Ruling
• Ex-Katten Atty Says Gov't Inflating Retrophin Losses
• FDA Clears Hospira's Biosimliar Of Amgen's Epogen
• 3rd Circ. Already OK'd Lipitor State Claims, Health Plans Say
• 6 States Sue Purdue Over Alleged Deceptive Opioid Marketing
• Insys Bribed Docs To Write Opioid Scripts, DOJ, 6 States Say
• Chancery Grants Class $3M In Legal Fees For Sorrento Suit
• Ex-Herbalife Sellers Fight Bid To Send $1B RICO Suit To Calif.
• CVS Seeks Exit From Proposed HIV Privacy Class Action
• FDA Warning Wire: Pesticides, Poisoning, YouTube Promos
• Class Attys Want $25M From $72.5M Medicis, Impax Deals
• Titan Of The Plaintiffs Bar: Seeger Weiss' Christopher Seeger
• Opioid Legislation May Expand Telehealth Coverage
• Keys To FDA Advisory Panel Prep For Device Makers
• Emerging Enforcement Trends For Patient Support Programs
• Alleged Valeant Betrayer's Boss Testifies He Was 'Concerned'
• Brand-Name Drug Cos. Not Liable For Generics' Tags In W.Va.
• Top Senate Dem Wants Info On Cohen-Novartis Dealings
• Fed. Circ. Upholds Toenail Drug IP Nix After Bass Challenge
• Fintech Co. GreenSky Tops 3 IPO Launches Totaling $951M
• J&J Can't Arbitrate Applicant's Background Check Claims
• USTR Prepares For Onslaught Of China Tariff Opposition
• Canada's Aurora Cannabis Scoops Up R&D Co. For $2.5B
• Recovering Lawyers' Lost Position Of Independence
• Overlooked Changes To Patent Cooperation Treaty Practice
• Texas Plans Opioid Deception Suit, Opposes State MDL
• BioChemics Not Covered For SEC Action, Axis Tells 1st Circ.
• Fed. Circ. Tells PTAB To Look Again At Eye Solution Patent
• Medical Device Co. Owes $2M For Contract Breach, Suit Says
• Trump Vows Cheaper Drugs 'Very Soon,' But That's Unlikely
• 23andMe Hits Ancestry.com With Patent Suit Over DNA Kit
• $45M Drug Milestone Suit Against Shire Kept Alive In Del.
• Bayer, Merck Sunblock SPF Suit Sent Back To State Court
• Dozens Of Cases Cut From Testosterone Replacement MDL
• Avee's Abbott Escrow Row Partly Nixed, But Open To Change
• Fed. Circ. Affirms Dismissal Of AIDS Drug Antitrust Case
• Taxation With Representation: Davis, Freshfields, Wachtell
• Health Hires: Katten, Seyfarth, Holland, Dechert, K&L Gates
• 'Anti-Aging Miracle' Does Nothing Of The Sort, Suit Says
• Lack Of Sameness Doomed INRatio Class Certification
• NJ Justices OK Centralizing Abilify Side-Effect Suits
• Trump To Unveil 4-Point Plan For Curbing Drug Prices
• Actiq Off-Label Marketing Suit Preempted, Pa. Panel Affirms
• NantKwest Says Investors Lack Standing For Some Claims
• Opioid MDL Judge Says Litigation Track Is A Settlement Aid
• 3 Firms Win 25% Fee Approval For $3.5M Ariad Deal
• Wachtell Reps Eli Lilly In $1.6B Deal For Oncology Drug Co.
• Scientist Asks 3rd Circ. To Rehear $5.8M Royalty Tax Case
• Firms Ask To Consolidate NJ Zostavax Suits Against Merck
• 8 Reasons To Take A Fresh Look At Your Law Office Lease
• Pomerantz, Shapiro Seek $5M Fees For $18M Aveo Stock Deal
• Shire Defends $2.4M Fee Request In Adderall Generic Row
• DOJ Sues To Stop Clinics' Unapproved Stem Cell Treatments
• Ex-Valeant Worker's Emails Show Double-Dealing, Jury Hears
• Attys Brawl Over Hospital Choice For Opioid MDL Bellwether
• A General Counsel's Tips For Succeeding As A New Associate
• Bristol Meyers, Pfizer Didn't Violate TCPA, 6th Circ. Says
• Pharma CEO Pleads Not Guilty Of $1.5M Fraud, For Now
• Thoratec Investors Win Cert. In Revived Stock-Drop Suit
• Novartis Says It Paid Michael Cohen $1.2M, Received Nothing
• CEO Asks 1st Circ. To Nix $3M 'Little Red Hen' Payout
• Patients Paid When Takeda Hid Actos Cancer Risks, Suit Says
• $117M Verdicts In J&J Talc Case Must Stand, Couple Says
• Neb. Tribes Sue Pharma Cos. Over 'Havoc' From Opioid Crisis
• VC-Backed Biotech, Louisiana Bank Price IPOs Raising $209M
• Ex-Pharmacist Denied Meningitis Acquittal Bid Amid Appeal
• Digital Medicine Co. Reaps $55M In Temasek-Led Fundraising
• Pay Attention To The Law And The Science Of Cannabidiol
• Some Soon-Shiong Claims Kept Alive In $47M Cash Tap Suit
• Jazz Pharmaceuticals To Pay $57M To End DOJ Inquiry
• Unclear If Shkreli's Attys Can Rep His Old Co., Judge Says
• Genentech Defends Herceptin Dosing Patents Before PTAB
• Drug Execs Deny Blame For Role In Opioid Crisis
• Widow Says Atty's Duty Included Safeguarding Frozen Sperm
• DEA Must Divulge National Data In Opioid MDL, Judge Rules
• 30 Calif. Counties Suing Opioid Makers, Distributors
• GSK Can't Make Hagens Berman Pay Special Master Fees
• Deals Rumor Mill: Walmart, Comcast, Bunge
• States Get 'Modest' Tax Help From Cannabis, Moody's Says
• Valeant To Pay Calif. Insurance Dept. $1.9M Over Philidor Ties
• Vanda Sues 2 Pharma Cos. Over Sleep Disorder Drug Patents
• McCarter & English Lands Ex-McDermott Patent Pro In Boston
• Arnold & Porter Sanctioned In Boston Scientific IP Case
• UK Cancer Biotech, Trucking Co. File IPOs Totaling $200M
• Diagnostics Co. Urges Justices To Deny Mayo Challenge
• Korean Investment Firm Pays $130.5M For GSK's Philly HQ
• Smarter, Faster, Stronger: A New Suite Of VC Model Docs
• A Cautiously Optimistic Diagnosis For Patent Eligibility
• Takeda Inks £46B Shire Takeover After Multiple Offers
• RxStrategies Says CVS, Rival Swiping Its Customers
• Endo Shareholders Fight Bid To Toss Opioid Safety Suit
• Opioid MDL Attys Must Disclose Outside Funding, Judge Says
• Fed. Circ. Affirms Damages In X-Ray Patent Row
• Drug Cos. Can Add Support To Pause Cherokee Opioid Suit
• Opana ER MDL Buyers Want Impax Docs About Endo Deal
• CytRx Investors Seek OK On $5.75M Stock Drop Settlement
• No Kickback Sanctions For Ostomy Samples, Watchdog Says
• DEA's Proposed Opioid Limits Meet Industry Resistance
• PTAB Won't Revisit Patent For Astellas Bladder Drug
• Boehringer Scores 2nd Bellwether Win In Conn. Pradaxa Suit
• Judging A Book: Berzon Reviews 'We The Corporations'
• Diabetic Care RX Case Is A Warning Sign For Private Equity
• What ABA's Position On Harassment Means For Employers
• Inside The New GMO Labeling Disclosure Proposal
• Titan of the Plaintiffs Bar: Baum Hedlund's R. Brent Wisner
• Law360 Reveals Titans Of The Plaintiffs Bar
• FDA Fights Challenges To E-Cig Regulations In DC Circ.
• Insurer Asks 4th Circ. To Nix $87M Heparin Coverage Ruling
• SEC Sues Ex-Biotech Exec Over $21M Boiler Room Scheme
• FDA Can't Evade Prior Orphan Drug Ruling, Eagle Says
• Kessler Topaz Wins Lead In Cancer Drug Stock-Drop Suit
• Becton At Center Of Antitrust Suit Over Syringes, Catheters
• DC Circ. Mulls $1.6B Cut To Hospitals' 340B Reimbursement
• Tribes From Wash., ND Pile Onto Opioid MDL
• 5 Firms To Steer IPOs Exceeding $3.9B, Led By Axa Unit
• Fed. Circ. Revives Row Over Origin Of Hair-Removal Patent
• Pharma Execs Cast Doubt On Valeant's Compliance Culture
• Loeb & Loeb Atty Says Shkreli Defamed Her While At Turing
• Pa. Judge OKs Redo In Flaherty Fardo Malpractice Row
• Last Insurer Settles With Mylan In $67M Antitrust Appeal
• Doctor Escapes Suit Over Shoddy Biomet Hip Replacements
• Cybersecurity Firm Carbon Black Tops 8 IPOs Totaling $733M
• Perkins Coie Nabs Tech, VC Partner From DLA Piper
• Shire's $2.4M Fee Bid In Adderall Row Too High, Rival Says
• Practical Considerations For Litigating Proportionality
• Los Angeles Latest To Sue Pharma Cos. Over Opioid Crisis
• Docs' Attys Seek $5.7M From $13.5M Botox Pricing Deal
• $10M Philidor Trial Opens With Focus On Valeant Kickback
• FDA Chief Targets Kickback Safe Harbor To Trim Drug Prices
• Fed. Circ. Won't Revive Hip Implant Patent Nixed By PTAB
• Fox Rothschild Picks Up IP Pro For NY Office
• Feds Urged To Get Generic Naloxone, Patents Be Damned
• 8th Circ. Asked To Revive Express Scripts Antitrust Suit
• Generic Drug Patent Suits Up In 2017, Especially In Delaware
• What To Know About NIST's Bayh-Dole Act Updates
• Surveying The CRISPR Patent War
• Supporting Nontraditional Data Types In E-Discovery
• Fresenius' Hits Akorn With Counterclaims Alleging Fraud
• VC-Backed Medical Device Co. Prices Upsized $108M IPO
• Cholesterol Test Strip Co. Wants ITC To Investigate Rival
• Pharma Industry Seeks Texas MDL For Opioid Cases
• Mylan Settles With Most Insurers In $67M Antitrust Appeal
• Biotech Firm, Streaming Co. Launch IPOs Totaling $225M
• Opioid Cos. Sued Over Ballooning Health Insurance Costs
• Fed. Circ. Prods Teva On Bid To Revive Nixed Dose Patents
• Thoratec Investors Seek Cert. In Revived Stock-Drop Suit
• PharMerica Beats Final Claims In 2007 Kickback Lawsuit
• Calif. Regulator OKs First Policy For Pot Biz Landlords
• Honigman Nabs Dinsmore Partner, 2 Attys For IP Group
• NJ Real Estate Considerations After Cannabis Legalization
• Ex-Biotech Exec To Admit Lying To SEC, Skip Fraud Retrial
• J&J Subsidiary's Breast Implants Caused Cancer, Suit Says